Royalty Pharma plc
RPRX
$31.28
$0.110.35%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5.13% | 5.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.13% | 5.10% | |||
| Cost of Revenue | 172.07% | -207.14% | |||
| Gross Profit | -45.78% | 143.90% | |||
| SG&A Expenses | 19.17% | 3.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 236.24% | -163.66% | |||
| Operating Income | -50.82% | 172.62% | |||
| Income Before Tax | -58.54% | 314.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.54% | 314.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 51.92% | -184.03% | |||
| Net Income | -61.72% | 433.30% | |||
| EBIT | -50.82% | 172.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -70.91% | 437.27% | |||
| Normalized Basic EPS | -66.25% | 198.39% | |||
| EPS Diluted | -70.87% | 437.04% | |||
| Normalized Diluted EPS | -55.32% | 198.27% | |||
| Average Basic Shares Outstanding | 31.58% | -0.75% | |||
| Average Diluted Shares Outstanding | -0.63% | -0.70% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 1.60% | -0.81% | |||
